Stephens downgraded R1 RCM from Overweight to Equal-Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 8/1/2024 | Overweight → Equal-Weight | Stephens | |
| 8/1/2024 | Outperform → Market Perform | Leerink Partners | |
| 8/1/2024 | Buy → Hold | Jefferies | |
| 4/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/20/2024 | $16.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $14.00 | Outperform | Leerink Partners |
| 1/3/2024 | $14.00 | Overweight | Barclays |
Morgan Stanley downgraded R1 RCM from Overweight to Equal-Weight
Stephens downgraded R1 RCM from Overweight to Equal-Weight
Leerink Partners downgraded R1 RCM from Outperform to Market Perform
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Shift4 Payments Inc. (NYSE:FOUR) will replace R1 RCM Inc. (NASD:RCM) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 20. TowerBrook Capital Partners and Clayton, Dublier & Rice will acquire R1 RCM in a transaction expected to be completed on or about November 19. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector November 20, 2024 S&P MidCap 400 Addition Shift4 Payments FOUR Financials S&P MidCap 400 Deletion R1 RCM RCM Health Care For more information about S&P Dow Jones Indices, ple
Rachel Wilson appointed as Chief Financial Officer (CFO) James Hardie Industries plc ((ASX: JHX, NYSE:JHX), the world's #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announced the appointment of Ms. Rachel Wilson as Chief Financial Officer, effective immediately. As a member of the global executive team, Ms. Wilson will report directly to Chief Executive Officer Aaron Erter. Ms. Wilson was appointed after Jason Miele stepped down as Chief Financial Officer. Mr. Miele will remain with the Company for three months as an advisor to the Chief Executive Officer for special projects and will thereafter depart the organization. "I would li
MURRAY, Utah, Aug. 12, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of Agnes Bundy Scanlan, president of The Cambridge Group LLC, to the company's board of directors, effective August 11, 2021. Ms. Bundy Scanlan has more than 30 years of experience across regulatory risk management, compliance, and consumer financial protection. She has served as president of The Cambridge Group LLC, a regulatory risk management advisory firm, since May 2020. Prior to this role, Ms. Bundy Scanlan served as senior advisor at Trelian
POSASR - R1 RCM Inc. /DE (0001910851) (Filer)
S-8 POS - R1 RCM Inc. /DE (0001910851) (Filer)
S-8 POS - R1 RCM Inc. /DE (0001910851) (Filer)
MURRAY, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. ("R1"), a leader in automating revenue management for healthcare providers, today announced that investment funds affiliated with TowerBrook Capital Partners ("TowerBrook") and Clayton, Dubilier & Rice ("CD&R") have completed their previously announced acquisition of R1. On August 1, 2024, TowerBrook, CD&R and R1 announced that they had entered into a definitive merger agreement under which all outstanding shares of R1 common stock that TowerBrook did not own would be acquired for $14.30 per share in cash, valuing R1 at approximately $8.9 billion. With the completion of the transaction, R1's common stock has ceased trading and w
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Shift4 Payments Inc. (NYSE:FOUR) will replace R1 RCM Inc. (NASD:RCM) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 20. TowerBrook Capital Partners and Clayton, Dublier & Rice will acquire R1 RCM in a transaction expected to be completed on or about November 19. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector November 20, 2024 S&P MidCap 400 Addition Shift4 Payments FOUR Financials S&P MidCap 400 Deletion R1 RCM RCM Health Care For more information about S&P Dow Jones Indices, ple
MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148.2 million, compared to adjusted EBITDA of $161.5 million in the same period last year. The quarter reflects impacts to both revenue and costs as
MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148.2 million, compared to adjusted EBITDA of $161.5 million in the same period last year. The quarter reflects impacts to both revenue and costs as
MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period last year.Adjusted EBITDA of $156.1 million, compared to adjusted EBITDA of $142.9 million in the same period last year. The quarte
MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice ("CD&R"), in an all-cash transaction with an enterprise value of approximately $8.9 billion. An investment vehicle controlled by TowerBrook is currently the beneficial owner of approximately 36% of the Company's outstanding shares of common stock, including the warrant held by TowerBrook.
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
8 analysts have shared their evaluations of R1 RCM (NASDAQ:RCM) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 5 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 4 1 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for R1 RCM, presenting an average target of $17.38, a high estimate of $20.00, and a low estimate of $15.00. Observing a 0.75% increase, t
Canaccord Genuity analyst Richard Close maintains R1 RCM (NASDAQ:RCM) with a Buy and maintains $15 price target.